Regarding the pathogenesis and associations of lichen planus, all of the following statements are true EXCEPT:

## Pathogenesis and Clinical Associations of Lichen Planus ### Immunopathogenesis **Key Point:** Lichen planus is a T-cell mediated autoimmune disorder with a well-characterized pathogenic mechanism. #### CD8+ T-Cell Involvement - **Primary mechanism**: CD8+ cytotoxic T lymphocytes recognize and attack basal keratinocytes - **Antigen presentation**: Likely involves altered self-antigens or viral antigens (e.g., HCV) presented on MHC class I - **Result**: Basal cell apoptosis, colloid body formation, and lichenoid interface dermatitis - **Supporting cells**: CD4+ T cells and macrophages also infiltrate but CD8+ cells are predominant **High-Yield:** CD8+ T-cell mediated cytotoxicity is the core pathogenic mechanism — this is consistently tested. ### Viral Associations #### Hepatitis C Virus (HCV) - **Strong association**: Particularly in Mediterranean (Italy, Spain), Middle Eastern, and Asian (Japan, Taiwan) populations - **Prevalence**: HCV seropositivity in LP patients ranges from 0–60% depending on geographic region - **Mechanism**: HCV antigens may cross-react with keratinocyte antigens, triggering T-cell response - **Clinical implication**: Patients with LP in endemic HCV regions should be screened for HCV **Clinical Pearl:** HCV-associated LP tends to be more severe and erosive, particularly affecting oral mucosa. #### Other Viral Associations - Hepatitis B virus (less common) - HIV (exacerbates LP) - Epstein-Barr virus (proposed but not proven) ### Genetic Predisposition | HLA Allele | Association | Population | |-----------|-------------|------------| | HLA-C | Increased risk | Multiple populations | | HLA-B | Increased risk | Multiple populations | | HLA-DQ | Variable | Specific populations | **Key Point:** Genetic susceptibility is multifactorial; HLA associations vary by ethnicity. ### Malignant Transformation Risk — THE EXCEPTION **Warning:** This is the critical distinction for the exam. | Variant | Malignant Transformation Rate | Clinical Context | |---------|-------------------------------|------------------| | **Oral LP** | **0.5–5%** (NOT 40–50%) | Erosive forms carry higher risk | | **Cutaneous LP** | <1% | Rare; mainly in hypertrophic variant | | **Genital LP** | <1% | Rare | **High-Yield:** The claim of 40–50% malignant transformation in oral LP is **FALSE and a major exam trap**. The actual rate is 0.5–5%, with erosive oral LP carrying the highest risk (~5%). The 40–50% figure is sometimes confused with other oral premalignant conditions (e.g., oral submucous fibrosis, erythroplakia). **Clinical Pearl:** While malignant transformation in oral LP is uncommon, long-term follow-up of erosive oral LP is recommended, and patients should be counseled about smoking and alcohol cessation. ### Summary Table: True vs. False Statements | Statement | True/False | Reason | |-----------|-----------|--------| | CD8+ T cells are primary mediators | **TRUE** | Core pathogenic mechanism | | HCV associated with LP | **TRUE** | Strong geographic association | | Oral LP has 40–50% malignant transformation | **FALSE** | Actual rate is 0.5–5% | | Genetic predisposition exists | **TRUE** | HLA-C, HLA-B associations documented | [cite:Harrison 21e Ch 297; Park 26e Ch 14]